These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38392960)

  • 41. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
    Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies.
    Scuteri D; Adornetto A; Rombolà L; Naturale MD; Morrone LA; Bagetta G; Tonin P; Corasaniti MT
    Front Pharmacol; 2019; 10():363. PubMed ID: 31024319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies.
    Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Raffaelli B; Reuter U
    J Headache Pain; 2021 Dec; 22(1):158. PubMed ID: 34972502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
    Silberstein SD; Reshef S; Cohen JM; Gandhi S; Seminerio M; Ramirez Campos V; Kessler Y; Thompson SF; Blumenfeld A
    Adv Ther; 2023 Feb; 40(2):445-459. PubMed ID: 36350532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity of biologic therapies for migraine: a review of current evidence.
    Cohen JM; Ning X; Kessler Y; Rasamoelisolo M; Campos VR; Seminerio MJ; Krasenbaum LJ; Shen H; Stratton J
    J Headache Pain; 2021 Jan; 22(1):3. PubMed ID: 33413094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
    Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
    Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review.
    Muddam MR; Obajeun OA; Abaza A; Jaramillo AP; Sid Idris F; Anis Shaikh H; Vahora I; Moparthi KP; Al Rushaidi MT; Nath TS
    Cureus; 2023 Sep; 15(9):e45560. PubMed ID: 37868560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients.
    Schweiger V; Bellamoli P; Taus F; Gottin L; Martini A; Nizzero M; Bonora E; Del Balzo G; Donadello K; Secchettin E; Finco G; Santis D; Polati E
    J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibodies for the prevention of migraine.
    Raffaelli B; Neeb L; Reuter U
    Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
    Soni P; Chawla E
    Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases.
    Kashiwagi K; Katsuki M; Kawamura S; Tachikawa S; Ono A; Koh A
    Neurol Int; 2023 Feb; 15(1):318-324. PubMed ID: 36976663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.
    Sevivas H; Fresco P
    Eur J Med Res; 2022 Jun; 27(1):86. PubMed ID: 35659086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society.
    Aleksovska K; Hershey AD; Deen M; Icco R; Lee MJ; Diener HC
    Cephalalgia; 2023 Oct; 43(10):3331024231206162. PubMed ID: 37879637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
    Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
    Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
    [No Abstract]   [Full Text] [Related]  

  • 60. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
    Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
    Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.